Related Experiment Video
Updated: Dec 14, 2025

Intralymphatic Immunotherapy and Vaccination in Mice
Published on: February 2, 2014
Intralymphatic immunotherapy improves grass pollen allergic rhinoconjunctivitis: A 3-year randomized
Søren Helbo Skaarup1, Johannes Martin Schmid1, Tina Skjold1
1Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark.
Intralymphatic allergen immunotherapy (ILIT) significantly reduced grass pollen allergy symptoms and medication use in the first season. A booster injection did not provide additional benefits in this 3-year study.
Area of Science:
- Immunology
- Allergy Research
- Clinical Trials
Background:
- Allergic rhinoconjunctivitis is a widespread health issue.
- Current allergen immunotherapy options suffer from poor patient adherence due to cost, complexity, and time commitment.
- Novel approaches to allergen immunotherapy are necessary.
Purpose of the Study:
- To evaluate the long-term efficacy of intralymphatic allergen immunotherapy (ILIT) for grass pollen rhinoconjunctivitis.
- To assess the impact of a booster ILIT injection on treatment outcomes.
- To develop and utilize a novel evaluation tool incorporating symptom scores and environmental allergen levels.
Main Methods:
- A 3-year, double-blind, randomized, placebo-controlled trial involving 36 patients with grass pollen rhinoconjunctivitis.
- Treatment groups received either 3 ILIT injections with an ILIT booster, 3 ILIT injections with a placebo booster, or 3 placebo injections with a placebo booster.
- Primary outcome measured by a combined symptom and medication score (cSMS), analyzed with a linear regression model. Secondary outcomes included changes in specific IgE and IgG4 levels and skin/nasal provocation tests.
Main Results:
- A significant reduction in cSMS was observed in the ILIT group during the first follow-up season (48.5% decrease), but not in subsequent seasons.
- A novel regression model indicated a 37% reduction in cSMS, independent of pollen counts.
- Booster injections showed no significant additional benefit. Significant changes in grass-specific IgE and IgG4 were noted in ILIT groups, but provocation tests remained unchanged.
Conclusions:
- Intralymphatic allergen immunotherapy (ILIT) offers a significant short-term benefit for grass pollen allergy symptoms and reduces the need for rescue medication.
- The effectiveness of ILIT appears concentrated in the initial season post-treatment.
- Booster injections do not enhance the therapeutic effect of ILIT in this study.
More Related Videos
06:34A Component-resolved Diagnostic Approach for a Study on Grass Pollen Allergens in Chinese Southerners with Allergic Rhinitis and/or Asthma
Published on: June 4, 2017
03:40Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
Published on: December 20, 2024
Related Concept Videos
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms: